Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Molecular Psychiatry (2022 )Cite this article
Previous proton magnetic resonance spectroscopy (1H-MRS) studies suggest a perturbation in glutamate and/or GABA in Major Depressive Disorder (MDD). However, no studies examine the ratio of glutamate and glutamine (Glx) to GABA (Glx/GABA) as it relates to depressive symptoms, which may be more sensitive than either single metabolite. Using a within-subject design, we hypothesized that reduction in depressive symptoms correlates with reduction in Glx/GABA in the anterior cingulate cortex (ACC). The present trial is a randomized clinical trial that utilized 1H-MRS to examine Glx/GABA before and after 8 weeks of escitalopram or placebo. Participants completed the 17-item Hamilton Depression Rating Scale (HDRS17) and underwent magnetic resonance spectroscopy before and after treatment. Two GABA-edited MEGA-PRESS acquisitions were interleaved with a water unsuppressed reference scan. GABA and Glx were quantified from the average difference spectrum, with preprocessing using Gannet and spectral fitting using TARQUIN. Linear mixed models were utilized to evaluate relationships between change in HDRS17 and change in Glx/GABA using a univariate linear regression model, multiple linear regression incorporating treatment type as a covariate, and Bayes Factor (BF) hypothesis testing to examine strength of evidence. No significant relationship was detected between percent change in Glx, GABA, or Glx/GABA and percent change in HDRS17, regardless of treatment type. Further, MDD severity before/after treatment did not correlate with ACC Glx/GABA. In light of variable findings in the literature and lack of association in our investigation, future directions should include evaluating glutamate and glutamine individually to shed light on the underpinnings of MDD severity. Advancing Personalized Antidepressant Treatment Using PET/MRI, ClinicalTrials.gov, NCT02623205.
Your institute does not have access to this article
Get full journal access for 1 year
All prices are NET prices. VAT will be added later in the checkout. Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Brown V, Pecina M. Neuroimaging studies of antidepressant placebo effects: challenges and opportunities. Front Psychiatry. 2019;10:1–8.
Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC et al. Glutamate and GABA systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81:886–97.
CAS PubMed Article Google Scholar
Brennan B, Admon R, Perriello C, LaFlamme E, Athey A, Pizzagalli D, et al. Acute change in anterior cingulate cortex GABA, but not glutamine/glutamate, mediates antidepressant response to citalopram. Psychiatry Res Neuroimaging. 2017;269:9–16.
Sanacora G, Gueorguieva R, Epperson C, Wu Y, Appel M, Rothman D, et al. Subtype-specific alterations in gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705–13.
CAS PubMed Article Google Scholar
Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1558–68.
CAS PubMed Article Google Scholar
Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman E, Matthews PM, et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharm. 2008;15:39–47.
Gabbay V, Mao X, Klein RG, Ely BA, Babb JS, Panzner AM et al. Anterior cingulate cortex γ-aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry. 2012;69:139–49.
CAS PubMed Article Google Scholar
Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA et al. Amino acid neurotransmitters assessed by 1h mrs: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009;65:792–800.
CAS PubMed PubMed Central Article Google Scholar
Abdallah C, Jackowski A, Sato JR, Mao X, Kang G, Cheema R, et al. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015;25:1082–90.
CAS PubMed PubMed Central Article Google Scholar
Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77.
CAS PubMed Article Google Scholar
Luykx J, Laban K, van den Heuvel M, Boks M, Mandl R, Kahn R, et al. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings. Neurosci Biobehav Rev. 2012;36:198–205.
CAS PubMed Article Google Scholar
Sanacora G, Mason G, Rothman D, Behar K, Hyder F, Petroff O, et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999;56:1043–7.
Yildiz-Yesiloglu AA,DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res Neuroimaging. 2006;147:1–28.
Gunduz-Bruce H, Silber C, Kaul I, Rothschild A, Riesenberg R, Sankoh A, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381:903–11.
CAS PubMed Article Google Scholar
Godfrey KE, Gardner AC, Kwon S, Chea W, Muthukumaraswamy SD. Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: a systematic review and meta-analysis. J Psychiatr Res. 2018;105:33–44.
Romeo BC W, Fossati P, Rotge J. Meta-analysis of central and peripheral γ-aminobutyric acid levels in patients with unipolar and bipolar depression. J Psychiatry Neurosci. 2018;43:58–66.
Abdallah C, Jiang L, DeFeyter H, Fasula M, Krystal J, Rothman D, et al. Glutamate metabolism in major depressive disorder. Am J Psychiatry. 2014;171:1320–7.
PubMed PubMed Central Article Google Scholar
Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson C, Deligiannidis K, Rubinow D, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392:1058–70.
CAS PubMed Article Google Scholar
Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews P, Cowen P. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry. 2004;161:368–70.
Sanacora G, Mason G, Rothman D, Krystal J. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663–5.
Levine J, Panchalingam K, Rapoport A, Gershon S, McClure R, Pettegrew J. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000;47:586–93.
CAS PubMed Article Google Scholar
Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry. 2010;68:785–94.
PubMed PubMed Central Article CAS Google Scholar
Dang YH, Ma XC, Zhang JC, Ren Q, Wu J, Gao CG, et al. Targeting of NMDA receptors in the treatment of major depression. Curr Pharm Des. 2014;20:5151–9.
CAS PubMed Article Google Scholar
Kim Y, Na K. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:117–26.
CAS PubMed Article Google Scholar
Kugaya A, Sanacora G, Verhoeff N, Fujita M, Mason GF, Seneca NM, et al. Cerebral benzodiazepine receptors in depressed patients measured with [123i]iomazenil SPECT. Biol Psychiatry. 2003;54:792–9.
CAS PubMed Article Google Scholar
Godlewska B, Near J, Cowen P. Neurochemistry of major depression: a study using magnetic resonance spectroscopy. Psychopharmacology. 2015;232:501–7.
CAS PubMed Article Google Scholar
Walter M, Henning A, Grimm S, Schulte R, Beck J, Dydak U, et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry. 2009;66:478–86.
CAS PubMed Article Google Scholar
Grimm S, Luborzewski A, Schubert F, Merkl A, Kronenberg G, Colla M, et al. Region-specific glutamate changes in patients with unipolar depression. J Psychiatr Res. 2009;46:1059–65.
Godlewska B, Masaki C, Sharpley A, Cowen P, Emir U. Brain glutamate in medication-free depressed patients: a proton MRS study at 7 Tesla. Psychol Med. 2018;48:1731–7.
Abdallah C, Hannestad J, Mason G, Holmes S, DellaGioia N, Sanacora G, et al. Metabotropic glutamate receptor 5 and glutamate involvement in major depressive disorder: a multimodal imaging study. Biol Psychiatry. 2017;2:449–56.
Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S et al. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry. 2019;24:952–64.
CAS PubMed Article Google Scholar
Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med. 2003;33:1277–84.
CAS PubMed Article Google Scholar
Pfleiderer B, Michael N, Erfurth A, Ohrmann P, Hohmann U, Wolgast M, et al. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res. 2003;122:185–92.
CAS PubMed Article Google Scholar
Sanacora G, Mason G, Rothman D, Hyder F, Ciarcia J, Ostroff R, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry. 2003;160:577–9.
Taylor MJ, Godlewska BR, Norbury R, Selvaraj S, Near J, Cowen PJ. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. Int J Neuropsychopharmacol. 2012;15:1541–6.
CAS PubMed Article Google Scholar
Sanacora G, Fenton L, Fasula M, Rothman D, Levin Y, Krystal J, et al. Cortical GABA concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry. 2006;59:284–6.
CAS PubMed Article Google Scholar
Abdallah C, Niciu M, Fenton L, Fasula M, Jiang L, Black A, et al. Decreased occipital cortical glutamate levels in response to successful cognitive behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom. 2014;83:298–307.
Legarreta MD, Sheth C, Prescot AP, Renshaw PF, McGlade EC, & Yurgelun-Todd DA. An exploratory proton MRS examination of gamma-aminobutyric acid, glutamate, and glutamine and their relationship to affective aspects of chronic pain. Neurosci Res. 2021;163:10–7.
Levar N, van Leeuwen JMC, Denys D, van Wingen GA. Divergent influences of anterior cingulate cortex GABA concentrations on the emotion circuitry. NeuroImage. 2017;158:136–44.
CAS PubMed Article Google Scholar
Horn D, Yu C, Steiner J, Buchmann J, Kaufmann J, Osoba A, et al. Glutamatergic and resting-state functional connectivity correlates of severity in major depression—the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci. 2010;4:1–10.
Northoff GS E. Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical, and neural network findings. Mol Psychiatry. 2014;19:966–77.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
CAS PubMed PubMed Central Article Google Scholar
First MB, Spitzer RL, Miriam G, Williams JBW. Structured clinical interview for DSM-IV-TR axis I disorders, research version, Patient Edition, (SCID-I/P). (Biometric Research Department, New York State Psychiatric Institute: New York, 2002).
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
CAS PubMed Article Google Scholar
Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303:47–53.
CAS PubMed PubMed Central Article Google Scholar
Landin R, DeBrota DJ, DeVries TA, Potter WZ, Demitrack MA. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics. 2000;56:271–8.
CAS PubMed Article Google Scholar
Hill KR, Gardus JD, Bartlett EA, Perlman G, Parsey RV, DeLorenzo C. Measuring brain glucose metabolism in order to predict response to antidepressant or placebo: a randomized clinical trial. Neuroimage Clin. 2021;32:102858.
PubMed PubMed Central Article Google Scholar
Lin A, Andronesi O, Bogner W, Choi IY, Coello E, Cudalbu C, et al. Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts’ consensus recommendations. NMR Biomed. 2021;34:e4484.
PubMed PubMed Central Article Google Scholar
Kreis R. The trouble with quality filtering based on relative Cramér‐Rao lower bounds. Magn Reson Med. 2016;75:15–18.
Landheer K, Juchem C. Are Cramér‐Rao lower bounds an accurate estimate for standard deviations in in vivo magnetic resonance spectroscopy? NMR Biomed. 2021;34:e4521.
Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266–72.
CAS PubMed Article Google Scholar
Saleh MG, Edden RAE, Chang L, Ernst T. Motion correction in magnetic resonance spectroscopy. Magn Reson Med. 2020;84:2312–26.
PubMed PubMed Central Article Google Scholar
Harris AD, Puts NA, Edden RA. Tissue correction for GABA-edited MRS: considerations of voxel composition, tissue segmentation, and tissue relaxations. J Magn Reson Imaging. 2015;42:1431–40.
PubMed PubMed Central Article Google Scholar
Harris AD, Nicolaas AJP, Edden RAE. Tissue correction for GABA‐edited MRS: considerations of voxel composition, tissue segmentation, and tissue relaxations. J Magn Reson Imaging. 2015;42:1431–40.
PubMed PubMed Central Article Google Scholar
Edden RA, Puts NA, Harris AD, Barker PB, Evans CJ. Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra. J Magn Reson Imaging. 2014;40:1445–52.
Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med. 1990;14:26–30.
CAS PubMed Article Google Scholar
Near J, Edden R, Evans CJ, Paquin R, Harris A, Jezzard P. Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain. Magn Reson Med. 2015;73:44–50.
Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo (1)H magnetic resonance spectroscopy data. Magn Reson Med. 2011;65:1–12.
CAS PubMed Article Google Scholar
Keysers C, Gazzola V, Wagenmakers E. Using Bayes factor hypothesis testing in neuroscience to establish evidence of absence. Nat Neurosci. 2020;23:788–99.
CAS PubMed PubMed Central Article Google Scholar
Colloca L, Barsky A. Placebo and nocebo effects. N Engl J Med. 2020;382:554–61.
CAS PubMed Article Google Scholar
Whiteford HA, Harris MG, McKeon G, Baxter A, Pennell C, Barendregt JJ, et al. Estimating remission from untreated major depression: a systematic review and meta-analysis. Psychol Med. 2013;43:1569–85.
CAS PubMed Article Google Scholar
Yang J, Zhang M, Ahn H, Zhang Q, Jin T, Li I, et al. Development and evaluation of a multimodal marker of major depressive disorder. Hum Brain Mapp. 2018;39:4420–39.
PubMed PubMed Central Article Google Scholar
Draganov M, Vives-Gilabert Y, Diego-Adelino J, Vicent-Gil M, Puigdemont D, Portella M. Glutamatergic and GABA-ergic abnormalities in First-episode depression. A 1-year follow-up 1H-MR spectroscopic study. J Affect Disord. 2020;266:572–7.
CAS PubMed Article Google Scholar
Njau S, Joshi S, Espinoza R, Leaver A, Vasavada M, Marquina A, et al. Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. J Psychiatr Neurosci. 2017;42:6–16.
Colic L, von During F, Denzel D, Demenescu LR, Lord AR, Martens L, et al. Rostral anterior cingulate glutamine/glutamate disbalance in major depressive disorder depends on symptom severity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4:1049–58.
Yang J, Shen J. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience. 2005;135:927–37.
CAS PubMed Article Google Scholar
Taylor MJ, Mannie Z, Norbury R, Near J, Cowen P. Elevated cortical glutamate in young people at increased familial risk of depression. Int J Neuropsychopharmacol. 2011;14:255–9.
CAS PubMed Article Google Scholar
Bobo WV, Angleró GC, Jenkins G, Hall-Flavin DK, Weinshilboum R, Biernacka JM. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. Hum Psychopharmacol. 2016;31:185–92.
CAS PubMed PubMed Central Article Google Scholar
Bespalov A, Steckler T, Skolnick P. Be positive about negatives-recommendations for the publication of negative (or null) results. Eur Neuropsychopharmacol. 2019;29:1312–20.
CAS PubMed Article Google Scholar
We would like to thank the Biostatistical Consulting Core at the Stony Brook University Renaissance School of Medicine, and the clinical team who coordinated participant screening and symptom scale rating: Greg Perlman, Juhayer Alam, Kate Bartolotta, Dr. Yashar Yousefzadeh-Fard, Michala Godstrey, Qurat-ul-ain Gulamhussein, Nichole Hoehn, Dan Holzmacher, Dr. Sridhar Kadiyala, Colleen Oliva, Nehal Vadhan, Jennifer Rubinstein, Dr. Laura Kunkel, and Dr. Lucian Manu. This study (ID # 570152) was approved by the IRB (3/20/2015–12/21/2021).
This study is funded by NIMH (National Institute of Mental Health) R01MH104512, Brain & Behavior Research Foundation, The Dana Foundation, and NYS Faculty Development Grant.
Department of Psychiatry and Behavioral Health, Stony Brook University, Stony Brook, NY, USA
G. Anjali Narayan, Kathryn R. Hill, Ramin V. Parsey & Christine DeLorenzo
Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, NY, USA
Kenneth Wengler & Christine DeLorenzo
Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA
Kenneth Wengler & Christine DeLorenzo
Department of Radiology, North Shore University Hospital, Manhasset, NY, USA
Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, USA
Department of Preventive Medicine, Stony Brook University, Stony Brook, NY, USA
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
CD and RVP designed the study and completed data collection. KW, XH, JW, and JY analyzed the data. GAN, KRH, and CD interpreted data and drafted the manuscript. All authors reviewed and edited the manuscript.
Correspondence to G. Anjali Narayan.
GAN has no financial disclosures or conflicts of interest to declare. KRH has no financial disclosures or conflicts of interest to declare. XH has no financial disclosures or conflicts of interest to declare. KW has no financial disclosures or conflicts of interest to declare. JY has no financial disclosures or conflicts of interest to declare. JW has no financial disclosures or conflicts of interest to declare. RVP has no financial disclosures or conflicts of interest to declare. CD has no financial disclosures or conflicts of interest to declare.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Narayan, G.A., Hill, K.R., Wengler, K. et al. Does the change in glutamate to GABA ratio correlate with change in depression severity? A randomized, double-blind clinical trial. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01730-4
DOI: https://doi.org/10.1038/s41380-022-01730-4
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Molecular Psychiatry (Mol Psychiatry) ISSN 1476-5578 (online) ISSN 1359-4184 (print)